HUP0001403A2 - Monofoszforil-lipid-A-t tartalmazó vizes immunológiai adjuváns összetételek - Google Patents

Monofoszforil-lipid-A-t tartalmazó vizes immunológiai adjuváns összetételek

Info

Publication number
HUP0001403A2
HUP0001403A2 HU0001403A HUP0001403A HUP0001403A2 HU P0001403 A2 HUP0001403 A2 HU P0001403A2 HU 0001403 A HU0001403 A HU 0001403A HU P0001403 A HUP0001403 A HU P0001403A HU P0001403 A2 HUP0001403 A2 HU P0001403A2
Authority
HU
Hungary
Prior art keywords
surfactant
lipid
derivative
antigen
weakened
Prior art date
Application number
HU0001403A
Other languages
English (en)
Inventor
R. Thomas Crane
Original Assignee
Ribi Immunochem Research, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ribi Immunochem Research, Inc. filed Critical Ribi Immunochem Research, Inc.
Publication of HUP0001403A2 publication Critical patent/HUP0001403A2/hu
Publication of HUP0001403A3 publication Critical patent/HUP0001403A3/hu

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H13/00—Compounds containing saccharide radicals esterified by carbonic acid or derivatives thereof, or by organic acids, e.g. phosphonic acids
    • C07H13/02—Compounds containing saccharide radicals esterified by carbonic acid or derivatives thereof, or by organic acids, e.g. phosphonic acids by carboxylic acids
    • C07H13/04—Compounds containing saccharide radicals esterified by carbonic acid or derivatives thereof, or by organic acids, e.g. phosphonic acids by carboxylic acids having the esterifying carboxyl radicals attached to acyclic carbon atoms
    • C07H13/06—Fatty acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55572—Lipopolysaccharides; Lipid A; Monophosphoryl lipid A

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Immunology (AREA)
  • Oncology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Pulmonology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)

Abstract

A gyengített lipid-A származékőt és felületaktív anyagőt vagyfelületaktív anyagőkat tartalmazó vizes adjűváns összetétel amelegvérű állatőkban egy fehérje antigénnel szembeni imműnőlógiaiválaszt megnöveli. A jelen találmány szerinti gyengített lipid-Aszármazékők közé a mőnőfőszfőril-lipid-A és a 3-O-deacilezettmőnőfőszfőri-lipid-A tartőzik. A felületaktív anyagőt vagyfelületaktív anyagők keverékeit őldószerben felőldják. Az 1,2-dipalmitőil-sn-glicerő-3-főszfőkőlin az előnyben részesítettfelületaktív anyag. Az elegy kialakításáhőz a felőldőtt felületaktívanyagőt a gyengített lipid-A származékhőz hőzzáadják. A gyengítettlipid-A származék és a felületaktív anyag mőláris aránya körülbelül 4: 1. Az őldószert elpárőlőgtatják és a keletkezett filmhez vizetadnak. A szűszpenziót 60 řC-őn kitisztűlásáig szőnikálják. Az adjűvánskiszereléssel kezelt állatők az adőtt antigénnel szemben megnövekedettellenanyagválaszt műtattak, valamint a limfőciták prőliferációját és acitőtőxikűs T-limfőciták válaszait megnövelték. Egy antigén és a vizesadjűváns összetétel intranazális beadása a szérűm és a nyálkahártyákáltal szekretált IgA termelését stiműlálja. ŕ
HU0001403A 1997-04-01 1998-04-01 Aqueous immunologic adjuvant compositions of monophosphoryl lipid a HUP0001403A3 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US83107397A 1997-04-01 1997-04-01
PCT/US1998/006528 WO1998043670A2 (en) 1997-04-01 1998-04-01 Aqueous immunologic adjuvant compositions of monophosphoryl lipid a

Publications (2)

Publication Number Publication Date
HUP0001403A2 true HUP0001403A2 (hu) 2000-09-28
HUP0001403A3 HUP0001403A3 (en) 2003-05-28

Family

ID=25258229

Family Applications (1)

Application Number Title Priority Date Filing Date
HU0001403A HUP0001403A3 (en) 1997-04-01 1998-04-01 Aqueous immunologic adjuvant compositions of monophosphoryl lipid a

Country Status (19)

Country Link
EP (1) EP0971739B1 (hu)
JP (1) JP5019494B2 (hu)
KR (1) KR100603884B1 (hu)
CN (2) CN1259052A (hu)
AT (1) ATE278419T1 (hu)
AU (1) AU743114B2 (hu)
BR (1) BR9811262A (hu)
CA (1) CA2284586C (hu)
DE (1) DE69826842T2 (hu)
ES (1) ES2227825T3 (hu)
HK (1) HK1026613A1 (hu)
HU (1) HUP0001403A3 (hu)
IL (2) IL132126A0 (hu)
NO (1) NO994760L (hu)
NZ (1) NZ338101A (hu)
PL (1) PL190237B1 (hu)
PT (1) PT971739E (hu)
TR (1) TR199902437T2 (hu)
WO (1) WO1998043670A2 (hu)

Families Citing this family (71)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6491919B2 (en) * 1997-04-01 2002-12-10 Corixa Corporation Aqueous immunologic adjuvant compostions of monophosphoryl lipid A
GB9706957D0 (en) 1997-04-05 1997-05-21 Smithkline Beecham Plc Formulation
GB9820525D0 (en) 1998-09-21 1998-11-11 Allergy Therapeutics Ltd Formulation
GB0000891D0 (en) * 2000-01-14 2000-03-08 Allergy Therapeutics Ltd Formulation
US20050019340A1 (en) 2000-10-18 2005-01-27 Nathalie Garcon Vaccines
DK1361890T3 (da) 2001-02-23 2011-06-27 Glaxosmithkline Biolog Sa Influenzavaccineformuleringer til intradermal indgift
US20030031684A1 (en) 2001-03-30 2003-02-13 Corixa Corporation Methods for the production of 3-O-deactivated-4'-monophosphoryl lipid a (3D-MLA)
GB0109297D0 (en) 2001-04-12 2001-05-30 Glaxosmithkline Biolog Sa Vaccine
MY134424A (en) 2001-05-30 2007-12-31 Saechsisches Serumwerk Stable influenza virus preparations with low or no amount of thiomersal
US20100221284A1 (en) 2001-05-30 2010-09-02 Saech-Sisches Serumwerk Dresden Novel vaccine composition
GB0321615D0 (en) 2003-09-15 2003-10-15 Glaxo Group Ltd Improvements in vaccination
NZ555889A (en) * 2004-12-17 2009-07-31 Staat Der Nederlanden Vert Doo Deacylation of LPS in gram negative bacteria
GB0503337D0 (en) 2005-02-17 2005-03-23 Glaxosmithkline Biolog Sa Compositions
GB0504436D0 (en) 2005-03-03 2005-04-06 Glaxosmithkline Biolog Sa Vaccine
KR20150036658A (ko) 2005-04-29 2015-04-07 글락소스미스클라인 바이오로지칼즈 에스.에이. 결핵균 감염을 예방 또는 치료하기 위한 신규한 방법
PL1909830T3 (pl) * 2005-08-02 2012-02-29 Novartis Vaccines And Diagnostics S R L Ograniczenie oddziaływania pomiędzy olejem w adiuwancie a środkiem powierzchniowo czynnym w antygenie
TWI457133B (zh) * 2005-12-13 2014-10-21 Glaxosmithkline Biolog Sa 新穎組合物
US8018440B2 (en) 2005-12-30 2011-09-13 Microsoft Corporation Unintentional touch rejection
ES2673046T3 (es) 2006-09-26 2018-06-19 Infectious Disease Research Institute Composición de vacuna que contiene un adyuvante sintético
US20090181078A1 (en) 2006-09-26 2009-07-16 Infectious Disease Research Institute Vaccine composition containing synthetic adjuvant
US8836648B2 (en) 2009-05-27 2014-09-16 Microsoft Corporation Touch pull-in gesture
CA2764374C (en) 2009-06-05 2019-11-19 Infectious Disease Research Institute Synthetic glucopyranosyl lipid adjuvants
FR2954703B1 (fr) 2009-12-28 2013-12-13 Chu Nantes Agonistes des recepteurs tlr 4 et 9 pour prevenir les complications septiques de l'immunodepression post-traumatique chez les patients hospitalises pour traumatismes severes
US9411504B2 (en) 2010-01-28 2016-08-09 Microsoft Technology Licensing, Llc Copy and staple gestures
US8261213B2 (en) 2010-01-28 2012-09-04 Microsoft Corporation Brush, carbon-copy, and fill gestures
US9519356B2 (en) 2010-02-04 2016-12-13 Microsoft Technology Licensing, Llc Link gestures
US9367205B2 (en) 2010-02-19 2016-06-14 Microsoft Technolgoy Licensing, Llc Radial menus with bezel gestures
US8799827B2 (en) 2010-02-19 2014-08-05 Microsoft Corporation Page manipulations using on and off-screen gestures
US9310994B2 (en) 2010-02-19 2016-04-12 Microsoft Technology Licensing, Llc Use of bezel as an input mechanism
US9454304B2 (en) 2010-02-25 2016-09-27 Microsoft Technology Licensing, Llc Multi-screen dual tap gesture
US8707174B2 (en) 2010-02-25 2014-04-22 Microsoft Corporation Multi-screen hold and page-flip gesture
US9075522B2 (en) 2010-02-25 2015-07-07 Microsoft Technology Licensing, Llc Multi-screen bookmark hold gesture
US8751970B2 (en) 2010-02-25 2014-06-10 Microsoft Corporation Multi-screen synchronous slide gesture
US8612874B2 (en) 2010-12-23 2013-12-17 Microsoft Corporation Presenting an application change through a tile
US8689123B2 (en) 2010-12-23 2014-04-01 Microsoft Corporation Application reporting in an application-selectable user interface
US9423951B2 (en) 2010-12-31 2016-08-23 Microsoft Technology Licensing, Llc Content-based snap point
US9383917B2 (en) 2011-03-28 2016-07-05 Microsoft Technology Licensing, Llc Predictive tiling
GB201106357D0 (en) 2011-04-14 2011-06-01 Pessi Antonello Composition and uses thereof
CN103596586A (zh) 2011-04-08 2014-02-19 免疫设计公司 免疫原性组合物及使用所述组合物诱导体液和细胞免疫反应的方法
US9104440B2 (en) 2011-05-27 2015-08-11 Microsoft Technology Licensing, Llc Multi-application environment
US9104307B2 (en) 2011-05-27 2015-08-11 Microsoft Technology Licensing, Llc Multi-application environment
US9158445B2 (en) 2011-05-27 2015-10-13 Microsoft Technology Licensing, Llc Managing an immersive interface in a multi-application immersive environment
US9658766B2 (en) 2011-05-27 2017-05-23 Microsoft Technology Licensing, Llc Edge gesture
US9557909B2 (en) 2011-09-09 2017-01-31 Microsoft Technology Licensing, Llc Semantic zoom linguistic helpers
US9146670B2 (en) 2011-09-10 2015-09-29 Microsoft Technology Licensing, Llc Progressively indicating new content in an application-selectable user interface
US9244802B2 (en) 2011-09-10 2016-01-26 Microsoft Technology Licensing, Llc Resource user interface
WO2013038185A1 (en) 2011-09-12 2013-03-21 Jonathan Norden Weber Methods and compositions for raising an immune response to hiv
CN107540730B (zh) 2012-05-16 2021-07-16 免疫设计公司 用于hsv-2的疫苗
EP2666785A1 (en) 2012-05-23 2013-11-27 Affiris AG Complement component C5a-based vaccine
EP2703483A1 (en) 2012-08-29 2014-03-05 Affiris AG PCSK9 peptide vaccine
WO2014043189A1 (en) 2012-09-14 2014-03-20 The Regents Of The University Of Colorado, A Body Corporate Conditionally replication deficient herpes viruses and use thereof in vaccines
US9582122B2 (en) 2012-11-12 2017-02-28 Microsoft Technology Licensing, Llc Touch-sensitive bezel techniques
EA032326B1 (ru) 2013-04-18 2019-05-31 Иммьюн Дизайн Корп. Монотерапия gla для применения в лечении рака
US9463198B2 (en) 2013-06-04 2016-10-11 Infectious Disease Research Institute Compositions and methods for reducing or preventing metastasis
US9477337B2 (en) 2014-03-14 2016-10-25 Microsoft Technology Licensing, Llc Conductive trace routing for display and bezel sensors
LT3122378T (lt) * 2014-03-26 2020-02-10 Glaxosmithkline Biologicals S.A. Mutantų stafilokokiniai antigenai
US10759836B2 (en) 2014-07-18 2020-09-01 University Of Washington Cancer vaccine compositions and methods of use thereof
EP3138579A1 (en) 2015-09-05 2017-03-08 Biomay Ag Fusion protein for use in the treatment of a hepatitis b virus infection
GB201614799D0 (en) 2016-09-01 2016-10-19 Glaxosmithkline Biologicals Sa Compositions
EP3295956A1 (en) 2016-09-20 2018-03-21 Biomay Ag Polypeptide construct comprising fragments of allergens
AU2018330165A1 (en) 2017-09-08 2020-04-02 Access To Advanced Health Institute Liposomal formulations comprising saponin and methods of use
TW201946650A (zh) 2018-03-12 2019-12-16 美商詹森藥物公司 針對腹內感染之疫苗
EP3569612A1 (en) 2018-05-18 2019-11-20 Biomay Ag Treatment and prevention of house dust mite allergies
AU2020240072A1 (en) 2019-03-18 2021-10-28 Glaxosmithkline Biologicals S.A. Bioconjugates of E. coli O-antigen polysaccharides, methods of production thereof, and methods of use thereof
CA3134045A1 (en) 2019-03-18 2020-09-24 Janssen Pharmaceuticals, Inc. Methods of producing bioconjugates of e. coli o-antigen polysaccharides, compositions thereof, and methods of use thereof
KR20220107166A (ko) 2019-10-02 2022-08-02 얀센 백신스 앤드 프리벤션 비.브이. 스타필로코커스 펩티드 및 사용 방법
BR112022013720A2 (pt) 2020-01-16 2022-10-11 Janssen Pharmaceuticals Inc Mutante fimh, composições com o mesmo e seu uso
US20220088165A1 (en) 2020-09-17 2022-03-24 Janssen Pharmaceuticals, Inc. Multivalent vaccine compositions and uses thereof
WO2022153166A1 (en) 2021-01-12 2022-07-21 Janssen Pharmaceuticals, Inc. Fimh mutants, compositions therewith and use thereof
EP4313135A1 (en) 2021-04-01 2024-02-07 Janssen Pharmaceuticals, Inc. Production of e. coli o18 bioconjugates
US20240180940A1 (en) * 2021-05-27 2024-06-06 Revelation Biosciences, Inc. Mpla compositions and methods of use

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4912094B1 (en) * 1988-06-29 1994-02-15 Ribi Immunochem Research Inc. Modified lipopolysaccharides and process of preparation
US5068191A (en) * 1989-08-31 1991-11-26 The Biomembrane Institute Purified histo-blood group a glycosyltransferase and antibodies thereto
US5552141A (en) * 1991-10-30 1996-09-03 Ribi; Hans O. Polymeric immunological adjuvants
ATE204762T1 (de) * 1993-03-23 2001-09-15 Smithkline Beecham Biolog 3-0-deazylierte monophosphoryl lipid a enthaltende impfstoff-zusammensetzungen

Also Published As

Publication number Publication date
DE69826842D1 (de) 2004-11-11
AU743114B2 (en) 2002-01-17
PL336698A1 (en) 2000-07-03
CN1326564C (zh) 2007-07-18
NO994760L (no) 1999-11-26
NO994760D0 (no) 1999-09-30
IL132126A0 (en) 2001-03-19
EP0971739A2 (en) 2000-01-19
NZ338101A (en) 2002-03-28
IL132126A (en) 2006-10-05
EP0971739B1 (en) 2004-10-06
CN1259052A (zh) 2000-07-05
PT971739E (pt) 2004-12-31
CN1575815A (zh) 2005-02-09
ATE278419T1 (de) 2004-10-15
WO1998043670A3 (en) 1998-12-30
TR199902437T2 (xx) 2000-01-21
KR100603884B1 (ko) 2006-07-24
JP5019494B2 (ja) 2012-09-05
DE69826842T2 (de) 2005-11-24
PL190237B1 (pl) 2005-11-30
WO1998043670A2 (en) 1998-10-08
CA2284586C (en) 2011-02-08
BR9811262A (pt) 2000-10-17
AU6947398A (en) 1998-10-22
CA2284586A1 (en) 1998-10-08
HUP0001403A3 (en) 2003-05-28
ES2227825T3 (es) 2005-04-01
KR20010005882A (ko) 2001-01-15
JP2001526640A (ja) 2001-12-18
HK1026613A1 (en) 2000-12-22

Similar Documents

Publication Publication Date Title
HUP0001403A2 (hu) Monofoszforil-lipid-A-t tartalmazó vizes immunológiai adjuváns összetételek
WO2000078353A3 (en) Aqueous immunologic adjuvant compositions of monophosphoryl lipid a
US4415491A (en) Synthetic vaccine peptide epitomes of hepatitis B surface antigen
JPS56110617A (en) Nutrient composition for young child
JP2007291128A (ja) モラクセラ属菌由来トランスフェリン受容体タンパク質
NO943739L (no) Vaksiner inneholdende vesikler basert på ikke-ioniske overflate-aktive midler
RU96123916A (ru) Применение циклодекстрина в качестве мукоадгезива, композиция на основе интраконазола и циклодекстрина и способ ее получения
CA2138925A1 (en) Method of producing reconstituted lipoproteins
DK0561907T3 (da) Proteiner med ændrede epitoper og fremgangsmåder til fremstilling deraf
ATE249844T1 (de) Immunologische kombinationsmittel und dazugehörige verfahren
NO863176D0 (no) Fremgangsmaate og blanding ved fremstilling av liposomer.
EP0203676A3 (en) Vaccine for generating an immunogenic t cell response protective against a virus
SE8205313L (sv) Antigen-proteinkomplex for blockering av allergiska reaktioner samt sett for framstellning derav
ES554921A0 (es) Procedimiento para la obtencion de derivados de oligopeptido, de efecto tensioactivo compatible con la piel
ATE239073T1 (de) Hemmung des tumorzellwachstums durch verabreichung von b7-transfizierten zellen
US5017558A (en) Synthetic vaccine peptide epitomes of hepatitis B surface antigen
US5292506A (en) Muramyldipeptide derivatives and influenza vaccine comprising the derivatives
BR9304205A (pt) Extrato à base de proteínas bacterianas, processo para preparação do extrato, e composição farmacêutica
ATE192735T1 (de) Verfahren zur herstellung von aminoxyd tenside enthaltenden festen zusammensetzungen
ES2084348T3 (es) N-((4,5-dihidroxi- y 4,5,8-trihidroxi-9,10-dihidro-9,10-dioxo-2-antracen-il)carbonil)aminoacidos utiles en la terapia de afecciones osteoarticulares.
LV12627A (lv) Aqueous prolonged release formulation
KR0178422B1 (ko) 한탄 바이러스의 펩타이드 항원을 함유하는 리포좀
KR100189701B1 (ko) B형 간염 바이러스의 x 단밸직 유래의 펩타이드 항원을 함유하는 리포좀
AOKI et al. Studies on the Emulsifying Properties of Soybean Proteins Part III. Effect of partial hydrolysis by dilute hydrochloric acid
Karmakar et al. Chemical modification studies on Cocos nucifera pollen allergens

Legal Events

Date Code Title Description
FD9A Lapse of provisional protection due to non-payment of fees